Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Simcere Pharmaceutical Group Limited ( (HK:2096) ).
Simcere Pharmaceutical Group reported 2025 revenue of RMB7.73 billion, up 16.5% year on year, driven by a 27.9% surge in its innovative pharmaceutical business to RMB6.30 billion, which now accounts for more than four-fifths of total sales. Growth was strongest in oncology and neuroscience, while revenue from other therapeutic areas declined.
Profit attributable to equity shareholders jumped 86.2% to RMB1.34 billion, with adjusted profit rising 27.1% to RMB1.28 billion, underscoring improving profitability as the business mix shifts further toward innovation-led products. The company also completed a common-control acquisition of Xianwei (Hainan) Biotechnology, restating 2024 figures and signaling continued consolidation to strengthen its competitive position across key therapeutic fields.
The most recent analyst rating on (HK:2096) stock is a Buy with a HK$16.30 price target. To see the full list of analyst forecasts on Simcere Pharmaceutical Group Limited stock, see the HK:2096 Stock Forecast page.
More about Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Group Limited is a Hong Kong–incorporated biopharmaceutical company focused on innovative prescription drugs, with a portfolio concentrated in neuroscience, autoimmune diseases and oncology. The group derives the majority of its revenue from its innovative pharmaceuticals segment, reflecting a strategic emphasis on high-value therapeutic areas in the Chinese healthcare market.
Average Trading Volume: 6,403,851
Technical Sentiment Signal: Buy
Current Market Cap: HK$28.76B
Find detailed analytics on 2096 stock on TipRanks’ Stock Analysis page.